Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. on December 28, 2018. The report details the entry into a material definitive agreement regarding the company's equity financing capabilities.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
Material Changes
On December 28, 2018, the Company amended its existing At Market Issuance Sales Agreement dated March 16, 2017. The primary change involves adding JonesTrading Institutional Services LLC as an additional agent alongside the existing agent, B. Riley FBR, Inc. (successor to FBR Capital Markets & Co.).
Guidance, Outlook, and Management Commentary
- Agreement Terms: Under the Amended Agreement, the agents will use commercially reasonable efforts to sell the Company's common stock based on instructions regarding price, time, size, and other parameters.
- Compensation: The Company will pay the agents a cash commission equal to 3.0% of the gross proceeds from any stock sold pursuant to the agreement.
- Documentation: A copy of the Amended Agreement is scheduled to be included as an exhibit to the Company's Form 10-K for the year ending December 31, 2018.
Investor Verification Checklist
- Verify the total amount of common stock authorized for sale under the original and amended agreements.
- Review the Form 10-K for the year ending December 31, 2018, to examine the full text of the Amended Agreement.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the current cash position of the Company to assess the impact of potential dilution from future sales.